Merck's decision to withdraw Vioxx cast suspicion on the safety of drugs in that class.
"The data for Celebrex is robust and exceeds, in the length of patients in studies and in the size of studies, the data Vioxx has," she said.
"The data for Celebrex is robust and exceeds, in the length of patients in studies and in the size of studies, the data Vioxx has," she said.
"I believe this is a class effect," he said, meaning that the problem also applies to Celebrex and Pfizer's newer, similar drug, Bextra, which remain on the market.
